The Role of Resistant Starch in COVID-19 Infection

COVID-19 Clinical Trial

Official title:

The Role of Resistant Starch in COVID-19 Infection

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04342689
• Other study ID #: 2000027887
• Status: Terminated
• Phase: Phase 2/Phase 3
• Start date: June 3, 2020
• Est. completion date: April 15, 2021

Study information

• Verified date: September 2022
• Source: Yale University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a multicenter randomized trial to evaluate the efficacy of administering a dietary supplement containing resistant starch to non-hospitalized COVID-19 positive subjects, The intervention will begin as soon as possible after subjects test positive for COVID-19 and continue for 14 days. Investigators hypothesize that short-term administration of a dietary supplement containing resistant starch has the potential to reduce rates of hospitalization and improve time to clinical recovery and symptoms in non-hospitalized COVID-19 positive patients.

Description:

The COVID-19 pandemic has caused a substantial strain on the healthcare system, with at least 14% of infected patients requiring hospitalization. Identifying ways to ameliorate the progression and severity of the COVID-19 infection and preventing hospitalization is critical. Patients suffering from COVID-19 have been shown to have a significant inflammatory response resembling that of cytokine release syndrome, and it is this inflammatory phase that is thought to drive fatality.

To this end, a multi-center randomized clinical trial to determine the efficacy of resistant starch in reducing the need for hospitalization for COVID-19 positive patients will be studied. This study will enroll 1500 non-hospitalized COVID-19 positive individuals who are being monitored in the outpatient setting. Patients will be randomized to either a dietary supplement containing resistant starch or a placebo for 14 days. Our primary outcome is the rate of hospitalization for COVID-19 related complications. Secondary outcomes will look at time to recovery and symptom severity scores.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 226
• Est. completion date: April 15, 2021
• Est. primary completion date: April 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• greater than 18 years of age

• COVID-positive status

• Being monitored in an outpatient setting at one of our study sites:

• Yale New Haven Hospital (YNHH)

• University of Michigan

• University of Minnesota

Exclusion Criteria:

• inflammatory bowel disease

• history of gastric bypass surgery

• active Clostridium difficile infection

• active participation in another COVID-19 interventional trial

• any physical or psychological condition that, in the opinion of the investigator, would pose unacceptable risk to the patient or raise concern that the patient would not comply with the protocol procedures.

• Reported allergy to starch

• Difficulty swallowing in order to prevent any aspiration risk

• Currently taking any IL-6 inhibitors such as Tocilizumab for any disease condition

Related Conditions & MeSH terms

• COVID-19

Intervention

Drug:
• Dietary Supplement containing resistant starch
Two tablespoons (~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)

Dietary Supplement:
• Placebo Starch
Two tablespoons (~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan
United States	Yale University	New Haven	Connecticut

Sponsors (2)

Lead Sponsor	Collaborator
Yale University	University of Michigan

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Count of Participant Hospitalization for a COVID-19 Related Complication (Phase 3)	Hospitalization for a COVID-19 related admission during the first month of follow up. Death prior to hospitalization thought to be secondary to COVID-19 will also be defined as an event.	One month from the start of treatment
Secondary	Time to Clinical Recovery (TTCR) (Phase 2)	Time to clinical recovery will be defined by a return to normal body temperature (97-99 degrees F) as reported by the patient, and resolution of major presenting symptoms (myalgia, cough, shortness of breath, and GI symptoms) maintained for 72 hours. Patients will be called every 2 days for the first 14 days of the study, and then once weekly for the following 14 days to assess symptoms via a pre-specified questionnaire. Patients will be followed from the start of treatment to the end of follow-up at 4 months.	One month from the start of treatment, up to 4 months
Secondary	Peak Symptom Severity Score (Phase 2)	This score will be evaluated using a subjective self-reporting questionnaire around 8 symptoms, which include: shortness of breath at rest or exertion, fatigue, myalgia/muscle aces, fever, cough, headache, GI symptoms, inability to taste or smell. Subjects will rate each of their symptoms on an ordinal scale as follows: absent (0), mild (1), moderate (2), or severe (3). These symptom ratings will be added to define the symptom severity score with a possible score range of 0-24 points. Subjects will be called every 2 days for the first 14 days of the study, and then once weekly for the following 14 days to assess symptoms via this pre-specified questionnaire. Patients will be followed from the start of treatment to the end of follow-up at 4 months. "Peak" was added to the outcome title (to correctly identify the measure) when results were entered.	One month from the start of treatment, up to 4 months